Combination of substances for regenerative therapy in patients with type 1 diabetes mellitus
a technology of regenerative therapy and diabetes mellitus, which is applied in the field of medicine, can solve the problems of patient's death, poisoning of the body, and disease that was regarded as fatal, and achieve the effect of favorable side effects
Pending Publication Date: 2021-12-09
LEVICURE LTD
View PDF0 Cites 2 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
The triple therapy significantly reduces insulin requirements, with over 50% of patients able to decrease their insulin doses, and in some cases, completely discontinue insulin use for long periods, demonstrating effective pancreatic function regeneration with low toxicity and favorable side effects.
Problems solved by technology
Additionally, a prolonged manifestation of the disease in the absence of diagnosis can lead to the poisoning of the body by some by-products of lipolysis (fat decomposition)—often expressed as ketone bodies production and specific odour coming from the skin and the mouth.
Until 1921, when insulin treatment was applied for the first time, this disease was regarded as fatal.
Without this treatment, the disease progresses rapidly and leads to severe complications such as diabetic retinopathy, polyneuropathy, diabetic foot ulcers, ketoacidosis, and diabetic coma, diabetic cardiomyopathy, kidney failure, etc., all of which may lead to disability or result in the patient's death.
However, a constant intake of insulin can often lead to an overdose, which can give rise to several complications.
The risk of hypoglycemia, which contributes to the development of brain damage, dementia, cardiovascular complications, atherosclerosis and arterial hypertension, is particularly high.
However, in the analysis, it was noted that not all participants were able to increase their glucagon-like peptide 1 and gastrin concentrations.
However, this combination does not provide a significant reduction of the insulin dose.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
example 2
[0049]19.5-year-old patient, diagnosed with type 1 diabetes since September 2015. Prior to his admission to the clinic, he has been treated with insulin Lantus (Glargine) 26 units in the morning, and with insulin Actrapid (Glulisin) three times a day during meals: 16-14-12 units. Analysis: unremarkable anamnesis, ketoacidosis, HIBa1C=12.8%. The results of the CGM study are shown in FIG. 3.
[0050]The patient was prescribed with an orally-administered combination in accordance with the invention. The combination included sitagliptin at 50 mg per day, pantoprazole at 10 mg per day, and GABA at 300 mg three times a day. FIG. 4 and FIG. 5 demonstrate an absence of the need for insulin. HBa1C=5.1%. The patient did not require any insulin for almost 1.5 years. Now he is well-controlled on 20-22 units of basal insulin only.
[0051]A total of 46 people took part in the research More than 50% of the patients were able to significantly reduce their insulin doses, with five patients stopping insul...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
This invention applies to the field of medicine, namely to endocrinology, and intended for the treatment of type 1 diabetes mellitus.The invention proposes a combination, containing a Dipeptidyl peptidase-4 (DPP-4) inhibitors, a proton pump inhibitors (PPI), and gamma-aminobutyric acid or a gamma-aminobutyric acid receptor agonists. This unique combination of medications and specific dosage of drugs leads to the regeneration (recovery) of the β-cells of the pancreas, which is presented by a dramatic reduction of insulin requirements up to a total insulin discontinuation in some persons.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 16 / 119,430, filed Aug. 31, 2018, which claims priority from Russian Application No. 2018104548, filed on Feb. 6, 2018, both of which are hereby incorporated by reference.FIELD OF THE INVENTION[0002]This invention relates to the field of medicine, namely, to endocrinology, and can be used to treat type 1 diabetes.BACKGROUND ART[0003]Diabetes mellitus type 1 (DM1, insulin-dependent diabetes, juvenile diabetes) is an autoimmune disease of the endocrine pancreas. Its main diagnostic sign is chronic hyperglycaemia (high blood sugar), polyuria (frequent urination), and other signs and symptoms as: thirst, weight loss, excessive or decreased appetite; severe general fatigue. Additionally, a prolonged manifestation of the disease in the absence of diagnosis can lead to the poisoning of the body by some by-products of lipolysis (fat decomposition)—often expressed as ketone bodi...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K31/4985A61K31/197A61K31/4439A61P3/10A61K31/5513A61K31/19A61K31/403A61K31/513
CPCA61K31/4985A61K31/197A61K31/4439A61K31/513A61K31/5513A61K31/19A61K31/403A61P3/10A61K31/546A61P5/50A61K31/155
InventorLEVIT, SHMUEL BORIS
OwnerLEVICURE LTD